Dr. DiNardo is an academic clinical investigator with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into risk assessments and treatment algorithms, the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups, and designing and executing successful clinical trials.

Key examples include Dr. DiNardo’s integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, ultimately assisting with the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).

Dr. DiNardo also leads the MD Anderson Hereditary Hematologic Malignancy Clinic (HHMC), which evaluates and follows individuals with cancer predisposition syndromes providing vital clinical and research opportunities for these underrecognized hereditary syndromes.